INDIANAPOLIS – (March 29,2022) – Companies around the world continue toshow strong interest in the Biomek NGeniuS Next Generation Library Prep Systemfrom Beckman Coulter Life Sciences and seek to develop demonstratedapplications on this easy-to-use new NGS automation platform, which reduceserrors and minimizes hands-on time.
Following a successful unveiling to the media andlab researchers at last month’s Society for Laboratory Automation and Screening(SLAS) International Conference & Exhibition in Boston, the companyannounces it has entered into an application development agreement with AmoyDx.
The collaboration will enable AmoyDx, aninnovative commercial-stage in vitro diagnostic (IVD) company, to develop newdemonstrated applications on the Biomek NGeniuS Liquid Handling System*. Thepurpose-built liquid handler for NGS library preparation reduces manualtransfers and the traditionally labor-intensive process of library construction.
“We are committed to accelerating applicationdevelopment and providing new NGS applications to further propel the researchjourney of our customers,” said Calvin Cortes, Biomek NGeniuS System ProductManager. “This is part of a robust series of development agreements, whichspeaks to the strength of the Biomek NGeniuS System coupled with the automationlibrary preparation portfolio of partners like AmoyDx.”
“To benefit tumor patients globally, and to bringvalue to customers, is our unwavering pursuit,” said Jiemin Luo, the RotatingGeneral Manager of AmoyDx. “Together with Beckman Coulter Life Sciences, AmoyDxwill bring advanced and reliable automated library preparation solutions foraccelerating and improving quality and efficiency of NGS research.”
As part of the partnership agreement, AmoyDx willdevelop applications specifically designed for the Biomek NGeniuS liquidhandler, which will be available to all users via a first-of-its-kindelectronic application library.
The Biomek NGeniuS System is scheduled to launchin the second quarter of 2022. More product information, resources, and previewscan be found at https://www.beckman.com/liquid-handlers/biomek-ngenius
About BeckmanCoulter Life Sciences
Life sciences. Research. Precision manufacturing.If your life’s calling is in any of these or related fields, you need to knowBeckman Coulter Life Sciences. Our mission is to empower those seeking answersto life’s important scientific and healthcare questions. Since 1935, theBeckman name has been synonymous with technologies that simplify and automatecomplex biomedical testing. Decades later, our global organization also came toembody the scientific legacy of the Coulter name. Today, Beckman Coulter LifeSciences is a trusted, worldwide resource for tools to help optimize researchand manufacturing efficiency. Centrifuges. Particle counters/analyzers.Automated liquid handlers. Flow cytometers. Genomic reagents. All theseproducts—and many more—continue to make a difference in people’s lives byimproving the productivity of dedicated scientists, quality control experts andothers. Wherever people need answers, from prestigious universities and majorpharmaceutical companies, to small biotech startups, food/beverage andelectronics manufacturing facilities, you can find Beckman Coulter LifeSciences. For more details, visit beckman.com/contact-us
About AmoyDiagnostics Co., Ltd.
Amoy Diagnostics Co., Ltd. is a pioneer andglobally leading company in the field of molecular diagnostics for precisiononcology, focusing on companion diagnostics product development andcommercialization. A rich product portfolio has been established with more thantwenty products approved by China NMPA, EU authority, Japan MHLW, South KoreaMFDS, etc. Patients in more than 60 countries are benefiting from AmoyDxproducts. With multiple technological platforms and full capability forcompanion diagnostics product development and commercialization, AmoyDx hasbecome an important diagnostics partner of many pharmaceutical companies overthe globe. For more information, please visit www.amoydiagnostics.com.
* Not intendedor validated for use in diagnosis of disease or other conditions. The BiomekNGeniuS Next Generation Library Prep System is in development; performancecharacteristics have not been validated.
Beckman Coulter, the stylized logo, and theBeckman Coulter product and service marks mentioned herein, including Biomekand Biomek NGeniuS, are trademarks or registered trademarks of Beckman Coulter,Inc. in the United States and other countries. All other trademarks are theproperty of their respective owners.
Contact: Matt McCutcheon, Global External CommunicationsManager
317-719-0557 mmccutcheon@beckman.com
INDIANAPOLIS – (March 29,2022) – Companies around the world continue toshow strong interest in the Biomek NGeniuS Next Generation Library Prep Systemfrom Beckman Coulter Life Sciences and seek to develop demonstratedapplications on this easy-to-use new NGS automation platform, which reduceserrors and minimizes hands-on time.
Following a successful unveiling to the media andlab researchers at last month’s Society for Laboratory Automation and Screening(SLAS) International Conference & Exhibition in Boston, the companyannounces it has entered into an application development agreement with AmoyDx.
The collaboration will enable AmoyDx, aninnovative commercial-stage in vitro diagnostic (IVD) company, to develop newdemonstrated applications on the Biomek NGeniuS Liquid Handling System*. Thepurpose-built liquid handler for NGS library preparation reduces manualtransfers and the traditionally labor-intensive process of library construction.
“We are committed to accelerating applicationdevelopment and providing new NGS applications to further propel the researchjourney of our customers,” said Calvin Cortes, Biomek NGeniuS System ProductManager. “This is part of a robust series of development agreements, whichspeaks to the strength of the Biomek NGeniuS System coupled with the automationlibrary preparation portfolio of partners like AmoyDx.”
“To benefit tumor patients globally, and to bringvalue to customers, is our unwavering pursuit,” said Jiemin Luo, the RotatingGeneral Manager of AmoyDx. “Together with Beckman Coulter Life Sciences, AmoyDxwill bring advanced and reliable automated library preparation solutions foraccelerating and improving quality and efficiency of NGS research.”
As part of the partnership agreement, AmoyDx willdevelop applications specifically designed for the Biomek NGeniuS liquidhandler, which will be available to all users via a first-of-its-kindelectronic application library.
The Biomek NGeniuS System is scheduled to launchin the second quarter of 2022. More product information, resources, and previewscan be found at https://www.beckman.com/liquid-handlers/biomek-ngenius
About BeckmanCoulter Life Sciences
Life sciences. Research. Precision manufacturing.If your life’s calling is in any of these or related fields, you need to knowBeckman Coulter Life Sciences. Our mission is to empower those seeking answersto life’s important scientific and healthcare questions. Since 1935, theBeckman name has been synonymous with technologies that simplify and automatecomplex biomedical testing. Decades later, our global organization also came toembody the scientific legacy of the Coulter name. Today, Beckman Coulter LifeSciences is a trusted, worldwide resource for tools to help optimize researchand manufacturing efficiency. Centrifuges. Particle counters/analyzers.Automated liquid handlers. Flow cytometers. Genomic reagents. All theseproducts—and many more—continue to make a difference in people’s lives byimproving the productivity of dedicated scientists, quality control experts andothers. Wherever people need answers, from prestigious universities and majorpharmaceutical companies, to small biotech startups, food/beverage andelectronics manufacturing facilities, you can find Beckman Coulter LifeSciences. For more details, visit beckman.com/contact-us
About AmoyDiagnostics Co., Ltd.
Amoy Diagnostics Co., Ltd. is a pioneer andglobally leading company in the field of molecular diagnostics for precisiononcology, focusing on companion diagnostics product development andcommercialization. A rich product portfolio has been established with more thantwenty products approved by China NMPA, EU authority, Japan MHLW, South KoreaMFDS, etc. Patients in more than 60 countries are benefiting from AmoyDxproducts. With multiple technological platforms and full capability forcompanion diagnostics product development and commercialization, AmoyDx hasbecome an important diagnostics partner of many pharmaceutical companies overthe globe. For more information, please visit www.amoydiagnostics.com.
* Not intendedor validated for use in diagnosis of disease or other conditions. The BiomekNGeniuS Next Generation Library Prep System is in development; performancecharacteristics have not been validated.
Beckman Coulter, the stylized logo, and theBeckman Coulter product and service marks mentioned herein, including Biomekand Biomek NGeniuS, are trademarks or registered trademarks of Beckman Coulter,Inc. in the United States and other countries. All other trademarks are theproperty of their respective owners.
Contact: Matt McCutcheon, Global External CommunicationsManager
317-719-0557 mmccutcheon@beckman.com